JPMorgan Chase & Co. Reiterates “Overweight” Rating for Spire Healthcare Group (LON:SPI)

JPMorgan Chase & Co. reiterated their overweight rating on shares of Spire Healthcare Group (LON:SPI) in a research note released on Thursday morning, MarketBeat Ratings reports. The brokerage currently has a GBX 344 ($4.28) price objective on the stock.

Separately, Berenberg Bank increased their price target on shares of Spire Healthcare Group from GBX 286 ($3.56) to GBX 300 ($3.73) and gave the company a buy rating in a research note on Wednesday.

Spire Healthcare Group Stock Performance

Spire Healthcare Group stock opened at GBX 249 ($3.10) on Thursday. The firm has a 50 day simple moving average of GBX 237.57 and a 200-day simple moving average of GBX 228.97. Spire Healthcare Group has a 1-year low of GBX 204 ($2.54) and a 1-year high of GBX 321.71 ($4.00). The company has a debt-to-equity ratio of 170.37, a current ratio of 0.69 and a quick ratio of 0.74. The stock has a market cap of £1.01 billion, a price-to-earnings ratio of 3,542.86, a price-to-earnings-growth ratio of 1.06 and a beta of 0.99.

Spire Healthcare Group Increases Dividend

The business also recently disclosed a dividend, which will be paid on Friday, June 21st. Investors of record on Thursday, May 23rd will be given a dividend of GBX 2.10 ($0.03) per share. The ex-dividend date of this dividend is Thursday, May 23rd. This represents a dividend yield of 0.89%. This is a boost from Spire Healthcare Group’s previous dividend of $0.50. Spire Healthcare Group’s dividend payout ratio (DPR) is presently 4,285.71%.

Spire Healthcare Group Company Profile

Spire Healthcare Group plc, together with its subsidiaries, owns and operates private hospitals and clinics. It offers various treatments in the areas of allergy and infectious diseases, blood tests, bones and joints, bowel treatments, breast screening and surgery, cancer investigations and treatments, cosmetic surgery, cyst removal, and dental surgery, as well as ear, nose, and throat treatments.